Core Insights - Hims & Hers Health, Inc. (HIMS) operates a consumer-first, digitally native healthcare platform that provides personalized care through telehealth, online pharmacy, and subscription services, focusing on chronic conditions like sexual health, hormone health, weight loss, dermatology, and mental health [1] Group 1: Business Model and Services - The company integrates licensed providers, proprietary technology, and cloud pharmacy infrastructure to support recurring treatment for various health conditions [1] - Recently, Hims & Hers has expanded into proactive and preventative care, launching Labs for data-driven testing and a multi-cancer early detection test in collaboration with GRAIL [2] - New offerings include menopause and perimenopause services on the Hers platform and exclusive oral testosterone treatments for men's health [2] Group 2: International Expansion - HIMS has entered Canada through the acquisition of Livewell and expanded its weight loss program to the U.K. [3] - The company announced plans to acquire Eucalyptus to enhance its presence in Europe and expand into Australia and Japan [3] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 65.4% over the past year, underperforming the industry decline of 29.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.3X, significantly lower than the industry average of 3.8X and its five-year median of 2.7X [10] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests flat performance compared to 2025 [8]

Core Insights - Profusa, Inc. has decided not to proceed with a $15 million public offering, as it reassessed its near-term capital needs based on updated revenue projections for 2026 and its collaboration with Mayo Clinic [1][2] - The company plans to pursue a smaller, more focused offering to support projected revenue from its Lumee Oxygen product in Europe starting in Q2 2026 and to invest in its collaboration with Mayo Clinic for U.S. market entry [1][2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, CA, focused on developing tissue-integrated sensors that provide continuous, actionable medical data [4] - The company aims to deliver long-lasting, injectable biosensors and an intelligent data platform to create personalized biochemical signatures for clinical use [4]

Core Insights - Healthcare Triangle's subsidiary QuantumNexis Inc. has launched operations in Dubai, UAE, aiming to enhance digital health transformation across the GCC countries [1] - The launch is part of a strategic expansion to support national healthcare modernization initiatives in the UAE, Saudi Arabia, Qatar, Oman, and Bahrain [1] - QuantumNexis integrates multiple brands and partnerships, including Ezovion Health OS, Ziloy.ai, and Better.care, to deliver AI-powered healthcare solutions [1] Market Opportunity - The GCC is identified as one of the fastest-growing digital health markets globally, driven by government investments and AI adoption [1] - The digital health market in Saudi Arabia is projected to exceed USD 11 billion by 2033, while the UAE's market is expected to reach USD 1.84 billion by 2030 [1] Strategic Focus Areas - Key focus areas for QuantumNexis include regulatory compliance, workforce capability development, digital mental health solutions, AI-powered automation, and interoperability [1] - The company aims to deliver compliant and AI-native healthcare solutions tailored to regional needs [1]

The prescription experience has started to resemble other parts of digital commerce: shoppers want clear pricing, fewer handoffs and a quicker path from decision to fulfillment.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional login ...

The stock’s decline follows a report that revealed revenue missed analyst expectations, adding pressure as broader markets experienced slight gains on the previous trading day.HIMS Q4 Earnings Miss Revenue ForecastsHims & Hers Health reported fourth-quarter revenue of $617.82 million, falling short of analyst estimates of $619.22 million. However, the company did beat earnings expectations with a reported 8 cents per share, surpassing estimates of 3 cents per share.The company noted that total revenue was u ...

The partnership will expand accessibility to Alberta Health-covered care, providing residents with access to licensed Alberta physicians virtually, from the location of their choice, with no user fees.Rocket Doctor’s platform will be tailored to Lethbridge County residents, supporting a wide range of needs including urgent care, chronic condition management / primary care, and mental health services.This collaboration addresses critical primary and urgent care gaps in rural communities, particularly for res ...

Hims & Hers Health (NYSE:HIMS) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAndrew Dudum - Co-founder and CEOBill Newby - Head of Investor RelationsEric Percher - Partner of Pharma Supply Chain and Digital HealthGlen Santangelo - Managing DirectorMaria Ripps - Managing Director of Equity ResearchMark Mahaney - Senior Managing Director and Head of Internet ResearchYemi Okupe - CFOConference Call ParticipantsBrian Tanquilut - Senior Analyst of Healthcare Services and Digital Health ...

Hims & Hers Health (NYSE:HIMS) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAndrew Dudum - Co-founder and CEOBill Newby - Head of Investor RelationsEric Percher - Partner of Pharma Supply Chain and Digital HealthGlen Santangelo - Managing DirectorMaria Ripps - Managing Director of Equity ResearchMark Mahaney - Senior Managing Director and Head of Internet ResearchYemi Okupe - CFOConference Call ParticipantsBrian Tanquilut - Senior Analyst of Healthcare Services and Digital Health ...

SAN RAMON, Calif.--(BUSINESS WIRE)-- #PregnancyJourney--MediKarma, the AI-driven platform that unifies and activates patient data to drive proactive care, today announced it has successfully completed the acquisition of Nanell, a specialized digital solution focused on the pregnancy journey, from Niterra Co., Ltd (Headquarters: Nagoya, Japan). The acquisition is set to integrate Nanell's intellectual property, product assets and operations directly into MediKarma's platform, strengthening its offering in Wo ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is establishing itself as a leading digital health platform focused on personalized, technology-enabled care, expanding its offerings across various life stages and health conditions [1][8] - The company has launched new specialties in women's health, including menopause and perimenopause, and in men's health with a low testosterone category, providing tailored treatment plans [1][8] - Hims & Hers is advancing into proactive, data-driven care with the introduction of Labs for comprehensive health monitoring and a multi-cancer early detection blood test [2][8] Company Developments - Hims & Hers has introduced a dedicated menopause and perimenopause specialty on the Hers platform, along with a low testosterone category on the HIMS platform, enhancing its service offerings [1][8] - The launch of Labs allows customers to monitor key health markers over time, supported by provider-guided action plans, and includes a multi-cancer early detection blood test for over 50 cancer types [2][8] - The company is making strategic investments in AI, diagnostics, and global expansion to create a connected healthcare platform that prioritizes personalized, preventive care [2][8] Financial Performance - Hims & Hers shares have decreased by 67.9% over the past year, underperforming the industry average decline of 32.8% [7] - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a significant improvement of 77.8% compared to 2024 [9] - HIMS' forward 12-month price-to-sales ratio is 1.3X, which is lower than the industry average of 3.7X and its five-year median of 2.7X, reflecting a Value Score of C [11]